China Pharma Holdings Long Term Debt

As of the most recent data (March 2026), CPHI shows a long-term debt of $92B. That compares with $1.4T in the prior-year period — down 93.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CPHI's long-term debt is now $92B (was $1.4T) — a 93.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether China Pharma Holdings is outperforming or lagging.

Tracking CPHI's long-term debt over time shows whether China Pharma Holdings is scaling, shrinking, or reshaping that part of the business. The current reading is $92B That compares with $1.4T in the prior-year period — down 93.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has China Pharma Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $92B) with ownership activity and broader fundamentals.

China Pharma Holdings's long-term debt is $92B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.